Airdoc 鹰瞳科技
HK-listed retinal AI for chronic-disease screening and myopia care
Overview
Beijing-based Airdoc (鹰瞳科技, 2251.HK) builds Retina-AI, which reads a fundus photo for retinal disease and systemic risks such as stroke and heart attack, plus a PBM-LED myopia-control device for children and a Neuro-AI stress monitor, all on its WanYu medical model. Retina-AI is registered in Singapore, Malaysia, Thailand, Vietnam, Indonesia and the Philippines.
Pricing
Pricing shown for reference only. These figures reflect RECATOOLS research as of 12 Oct 2026 and may be out of date or incomplete. This is not financial or purchasing advice — always confirm the current price on the provider’s official website before making any decision.
- Software alone or bundled with Airdoc fundus cameras
- No public price list
- Two 3-minute sessions a day, at least 4 hours apart
- Vendor says it does not replace glasses or professional eye care
- Listed with a buy button on airdoc.com; local price may differ
What you can produce with Airdoc 鹰瞳科技
- Retinal disease and systemic risks such as heart attack, stroke and dementia screened from one non-dilated fundus photo
- Airdoc-AIFUNDUS, NMPA Class III-certified for diabetic retinopathy (Aug 2020) and retinal vein occlusion (Apr 2025)
- CE MDR-certified fundus AI in Europe, and registered Retina-AI in six ASEAN markets including Singapore and Malaysia
- Image capture with Airdoc's fully automatic, mydriasis-free fundus cameras, such as the 12 MP AI-FD16H
- Home myopia-management sessions for children with the PBM-LED vision rehabilitation device
- A 90-second contactless stress-resilience test with Neuro-AI (NMPA Class II, March 2026)
- Referral of flagged cases from community screening to hospitals through 8,500+ active Retina-AI sites
Airdoc's retinal AI has an unusually strong regulatory record: NMPA Class III approval for diabetic retinopathy in August 2020 and for retinal vein occlusion in April 2025, CE MDR certification for its fundus software, and registrations across Singapore, Malaysia, Thailand, Vietnam, Indonesia and the Philippines. It sells software alone or with its own non-mydriatic fundus cameras, so it slots into health-check and primary-care screening.
The business is less settled. First-half 2026 revenue fell 19.6% and the company returned to a loss of RMB48.9 million, with growth coming from a ¥13,800 home myopia light-therapy device for children that Airdoc says does not replace glasses or eye care. There is no self-serve product or public screening price.
What we found
Airdoc is not reviewed by consumers; it sells through hospitals, health-check centres, optical outlets and distributors. The best evidence is its own Hong Kong filings, and they show a company shifting its weight from retinal screening towards myopia care.
The regulatory record is the strongest part. Its Airdoc-AIFUNDUS software won an NMPA Class III certificate for diabetic retinopathy in August 2020, which Airdoc calls the first such certificate in China, and a second Class III approval covering retinal vein occlusion in April 2025. Version 1.0 also gained EU CE MDR certification in 2023. Outside China, Retina-AI is registered in Singapore, Malaysia, Thailand, Vietnam, Indonesia and the Philippines, and the myopia product in Singapore, Malaysia and Vietnam, which gives it genuine regulatory reach in ASEAN. Earlier versions of this page said no ASEAN distribution was confirmed.
The finances are weaker. Revenue for 2025 was RMB173.3 million with a loss for the year of RMB24.4 million, a large improvement on the RMB265.1 million loss of 2024. The first half of 2026 went backwards: revenue fell 19.6% to RMB67.3 million and the loss attributable to shareholders was RMB48.9 million. Retina-AI revenue dropped 35.6% and the average fee per test fell 28% to RMB11.6, even though active sites rose to 8,523 and cumulative tests passed 37 million. The growth is now in myopia control, where PBM revenue rose 24% to RMB27.9 million across 5,424 outlets. Airdoc held RMB565.4 million in cash at the end of June.
Some numbers need care. The website says 40 million screenings while the interim report says over 37 million, and an earlier validation-study claim on this page could not be traced to a publication. The ¥13,800 PBM device is a home light-therapy aid for children that Airdoc itself says does not replace glasses or eye care. Health systems and insurers will find a serious, well-registered vendor; families should get a professional assessment before buying.
Compiled by RECATOOLS from public sources: vendor documentation and pricing, code repositories and published reporting.
About this listing
This entry was compiled from publicly available data including Airdoc 鹰瞳科技's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with Airdoc 鹰瞳科技 unless explicitly stated.
Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.
For the latest details, please refer to Airdoc 鹰瞳科技 directly →
Spotted something out of date? Suggest an update →
Related reading
Alternatives to Airdoc 鹰瞳科技
More in Healthcare
